Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2026
GLP-1 Receptor Agonists in the Male Aesthetic Practice: Opportunities for the Dermatologic Surgeon.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Badalian Hrag, Minokadeh Ardalan
Аннотация
BACKGROUND AND OBJECTIVES: The demand for male aesthetic treatments continues to rise, and with increased utilization of the glucagon-like peptide-1 receptor agonists (GLP-1RAs), we anticipate a growing need to address these concerns. This narrative review examined the intersection of skin-related effects of GLP-1RAs and male aesthetics, focusing on the role of the dermatologic surgeon in their management.
METHODS: A search of the available peer-reviewed literature through March 2026 in the PubMed database was conducted. Search terms included combinations of terms related to GLP-1RAs, male aesthetics, and dermatologic treatments. Studies were included if they were peer-reviewed, published in English, and relevant to the topic.
RESULTS: Many concerns that drive men to seek aesthetic treatments overlap with secondary cutaneous manifestations of GLP-1RA treatments including hair loss, changes in facial and body volume, and skin quality and laxity. Management options include, but are not limited to, dermal fillers for volume restoration and biostimulatory agents for skin laxity, along with medical and procedural interventions for hair loss.
CONCLUSION: Dermatologic surgeons are well-positioned to address GLP-1 receptor agonist-related aesthetic concerns in male patients. Practitioners should be prepared to offer evidence-based, customized treatment strategies as this population grows.
METHODS: A search of the available peer-reviewed literature through March 2026 in the PubMed database was conducted. Search terms included combinations of terms related to GLP-1RAs, male aesthetics, and dermatologic treatments. Studies were included if they were peer-reviewed, published in English, and relevant to the topic.
RESULTS: Many concerns that drive men to seek aesthetic treatments overlap with secondary cutaneous manifestations of GLP-1RA treatments including hair loss, changes in facial and body volume, and skin quality and laxity. Management options include, but are not limited to, dermal fillers for volume restoration and biostimulatory agents for skin laxity, along with medical and procedural interventions for hair loss.
CONCLUSION: Dermatologic surgeons are well-positioned to address GLP-1 receptor agonist-related aesthetic concerns in male patients. Practitioners should be prepared to offer evidence-based, customized treatment strategies as this population grows.